Emicizumab in Severe Hemophilia A: Clinical and Patient Determinants of Transition Within a Standardized Program

Using a standardized transition program offered an opportunity to gain a deeper understanding of patient and clinical factors associated with transition to a novel agent. This analysis highlights that certain clinical factors may influence uptake of new therapies within hemophilia care and the importance of early identification of barriers to facilitate treatment uptake.